Connect your AI

Novavax NVAX Investment Purchases

Investment Purchases at other companies

ModernaMRNA

$1.35B-23.6%

Merck & Co.MRK

$374M-37.1%

Vaxcyte, Inc.PCVX

$584.13M+85.7%

Viridian Therapeutics, Inc.VRDN

$91.32M+28.2%

ALN

Alnylam PharmaceuticalsALNY

$261.63M-34.9%

Gilead SciencesGILD

$525M—

Other financials

Income statement

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Novavax's investment purchases?: Novavax (NVAX) reported investment purchases of $214.13M in Q1 2026.
How has Novavax's investment purchases changed year-over-year?: Novavax's investment purchases increased by 86.6% year-over-year, from $114.72M to $214.13M.
What does investment purchases mean?: Cash spent purchasing investment securities across all categories.